DANGER is involved in high glucose-induced radioresistance through inhibiting DAPK-mediated anoikis in non-small cell lung cancer

Oncotarget

Volumn 7, Issue 6, 2016, Pages 7193-7206

  Kwon, TaeWoo ^a   Youn, HyeSook ^a   Son, Beomseok ^a   Kim, Daehoon ^a   Ki Moon Seong, ^b   Park, Sungkyun ^a   Kim, Wanyeon ^a   Youn, BuHyun ^a  

^a Pusan National University   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Anoikis; DANGER; DAPK; High glucose; Radioresistance

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; DAPK1 PROTEIN, HUMAN; ITPRIP PROTEIN, HUMAN; LUCIFERASE; MEMBRANE PROTEIN; SWEETENING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; ARTICLE; CATALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MALE; MOUSE; MTT ASSAY; NON SMALL CELL LUNG CANCER; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; ADVERSE EFFECTS; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FLUORESCENCE MICROSCOPY; GAMMA RADIATION; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL CULTURE;

ANIMALS; ANOIKIS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DEATH-ASSOCIATED PROTEIN KINASES; GAMMA RAYS; GLUCOSE; HUMANS; LUCIFERASES; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; RADIATION TOLERANCE; SWEETENING AGENTS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84981240926     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6887     Document Type: Article

References (51)

1. Koh PK, Faivre-Finn C, Blackhall FH, De Ruysscher D. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combina-tion with thoracic radiotherapy. Cancer Treat Rev. 2012; 38:626-640.
2. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresis-tance mechanisms in head and neck cancer. Lancet Oncol. 2008; 9:288-296.
3. Nishimura Y, Nakagawa K, Takeda K, Tanaka M, Segawa Y, Tsujino K, Negoro S, Fuwa N, Hida T, Kawahara M, Katakami N, Hirokawa K, Yamamoto N, et al. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002). Int J Radiat Oncol Biol Phys. 2007; 69:786-792.
4. Yang HJ, Youn H, Seong KM, Jin YW, Kim J, Youn B. Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells. J Biol Chem. 2013; 288:2965-2975.
5. Kim E, Youn H, Kwon T, Son B, Kang J, Yang HJ, Seong KM, Kim W, Youn B. PAK1 tyrosine phosphorylation is required to induce epithelial-mesenchymal transition and radioresistance in lung cancer cells. Cancer Res. 2014; 74:5520-5531.
6. Kim W, Youn H, Kwon T, Kang J, Kim E, Son B, Yang HJ, Jung Y, Youn B. PIM1 kinase inhibitors induce radiosensi-tization in non-small cell lung cancer cells. Pharmacol Res. 2013; 70:90-101.
7. Deppen SA, Blume JD, Kensinger CD, Morgan AM, Aldrich MC, Massion PP, Walker RC, McPheeters ML, Putnam JB, Jr., Grogan EL. Accuracy of FDG-PET to diag-nose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA. 2014; 312:1227-1236.
8. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009; 50:88-99.
9. Abramyuk A, Tokalov S, Zophel K, Koch A, Szluha Lazanyi K, Gillham C, Herrmann T, Abolmaali N. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol. 2009; 91:399-404.
10. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999; 40:556-565.
11. Ghooshkhanei H, Treglia G, Sabouri G, Davoodi R, Sadeghi R. Risk stratification and prognosis determina-tion using (18)F-FDG PET imaging in endometrial cancer patients: a systematic review and meta-analysis. Gynecol Oncol. 2014; 132:669-676.
12. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol. 2013; 19:4808-4817.
13. Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys. 2009; 73:1228-1234.
14. Jeong J, Setton JS, Lee NY, Oh JH, Deasy JO. Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. Radiother Oncol. 2014; 111:340-347.
15. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4:891-899.
16. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic require-ments of cell proliferation. Science. 2009; 324:1029-1033.
17. van Rossum DB, Patterson RL, Cheung KH, Barrow RK, Syrovatkina V, Gessell GS, Burkholder SG, Watkins DN, Foskett JK, Snyder SH. DANGER, a novel regulatory pro-tein of inositol 1,4,5-trisphosphate-receptor activity. J Biol Chem. 2006; 281:37111-37116.
18. Kang BN, Ahmad AS, Saleem S, Patterson RL, Hester L, Dore S, Snyder SH. Death-associated protein kinase-medi-ated cell death modulated by interaction with DANGER. J Neurosci. 2010; 30:93-98.
19. Miao F, Chen Z, Zhang L, Wang J, Gao H, Wu X, Natarajan R. RNA-sequencing analysis of high glucose-treated monocytes reveals novel transcriptome signatures and associated epigenetic profiles. Physiol Genomics. 2013; 45:287-299.
20. Bialik S, Kimchi A. The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem. 2006; 75:189-210.
21. Lin Y, Hupp TR, Stevens C. Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS J. 2010; 277:48-57.
22. Bajbouj K, Poehlmann A, Kuester D, Drewes T, Haase K, Hartig R, Teller A, Kliche S, Walluscheck D, Ivanovska J, Chakilam S, Ulitzsch A, Bommhardt U, et al. Identification of phosphorylated p38 as a novel DAPK-interacting part-ner during TNFalpha-induced apoptosis in colorectal tumor cells. Am J Pathol. 2009; 175:557-570.
23. Chakilam S, Gandesiri M, Rau TT, Agaimy A, Vijayalakshmi M, Ivanovska J, Wirtz RM, Schulze-Luehrmann J, Benderska N, Wittkopf N, Chellappan A, Ruemmele P, Vieth M, et al. Death-associated protein kinase controls STAT3 activity in intestinal epithelial cells. Am J Pathol. 2013; 182:1005-1020.
24. Ivanovska J, Tregubova A, Mahadevan V, Chakilam S, Gandesiri M, Benderska N, Ettle B, Hartmann A, Soder S, Ziesche E, Fischer T, Lautscham L, Fabry B, et al. Identification of DAPK as a scaffold protein for the LIMK/cofilin complex in TNF-induced apoptosis. Int J Biochem Cell Biol. 2013; 45:1720-1729.
25. Bialik S, Kimchi A. The DAP-kinase interactome. Apoptosis. 2014; 19:316-328.
26. Chen CH, Wang WJ, Kuo JC, Tsai HC, Lin JR, Chang ZF, Chen RH. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J. 2005; 24:294-304.
27. Nakadate Y, Kodera Y, Kitamura Y, Tachibana T, Tamura T, Koizumi F. Silencing of poly(ADP-ribose) glycohydro-lase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint. Biochem Biophys Res Commun. 2013; 441:793-798.
28. Li R, Uttarwar L, Gao B, Charbonneau M, Shi Y, Chan JS, Dubois CM, Krepinsky JC. High Glucose Up-regulates ADAM17 through HIF-1alpha in Mesangial Cells. J Biol Chem. 2015; 290:21603-21614.
29. Kim JJ, Tan Y, Xiao L, Sun YL, Qu X. Green tea polyphe-nol epigallocatechin-3-gallate enhance glycogen synthesis and inhibit lipogenesis in hepatocytes. Biomed Res Int. 2013; 2013:920128.
30. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA. 2008; 105:10762-10767.
31. Kuo JC, Lin JR, Staddon JM, Hosoya H, Chen RH. Uncoordinated regulation of stress fibers and focal adhe-sions by DAP kinase. J Cell Sci. 2003; 116:4777-4790.
32. Shohat G, Spivak-Kroizman T, Cohen O, Bialik S, Shani G, Berrisi H, Eisenstein M, Kimchi A. The pro-apoptotic function of death-associated protein kinase is controlled by a unique inhibitory autophosphorylation-based mechanism. J Biol Chem. 2001; 276:47460-47467.
33. Anjum R, Roux PP, Ballif BA, Gygi SP, Blenis J. The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol. 2005; 15:1762-1767.
34. Chang CC, Yang MH, Lin BR, Chen ST, Pan SH, Hsiao M, Lai TC, Lin SK, Jeng YM, Chu CY, Chen RH, Yang PC, Chin YE, et al. CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation. Cell Death Differ. 2013; 20:443-455.
35. Wang WJ, Kuo JC, Yao CC, Chen RH. DAP-kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals. J Cell Biol. 2002; 159:169-179.
36. Guadamillas MC, Cerezo A, Del Pozo MA. Overcoming anoikis--pathways to anchorage-independent growth in can-cer. J Cell Sci. 2011; 124:3189-3197.
37. Huang RY, Wong MK, Tan TZ, Kuay KT, Ng AH, Chung VY, Chu YS, Matsumura N, Lai HC, Lee YF, Sim WJ, Chai C, Pietschmann E, et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mes-enchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 2013; 4:e915.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
39. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011; 27:441-464.
40. Janssen MH, Aerts HJ, Ollers MC, Bosmans G, Lee JA, Buijsen J, De Ruysscher D, Lambin P, Lammering G, Dekker AL. Tumor delineation based on time-activity curve differ-ences assessed with dynamic fluorodeoxyglucose positron emission tomography-computed tomography in rectal cancer patients. Int J Radiat Oncol Biol Phys. 2009; 73:456-465.
41. Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck can-cer: a meta-analysis. J Cancer Res Clin Oncol. 2011; 137:1085-1093.
42. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, Brown PO, Botstein D, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001; 98:13784-13789.
43. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F, Philipsen S. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 2010; 5:e10312.
44. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001; 98:13790-13795.
45. Buchheit CL, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014; 14:632-641.
46. Slattum GM, Rosenblatt J. Tumour cell invasion: an emerg-ing role for basal epithelial cell extrusion. Nat Rev Cancer. 2014; 14:495-501.
47. Feofanova N, Geraldo JM, de Andrade LM. Radiation oncology in vitro: trends to improve radiotherapy through molecular targets. Biomed Res Int. 2014; 2014:461687.
48. Yang HJ, Youn H, Seong KM, Yun YJ, Kim W, Kim YH, Lee JY, Kim CS, Jin YW, Youn B. Psoralidin, a dual inhibi-tor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation. Biochem Pharmacol. 2011; 82:524-534.
49. Niyazi M, Niyazi I, Belka C. Counting colonies of clono-genic assays by using densitometric software. Radiat Oncol. 2007; 2:4.
50. Kang J, Kim E, Kim W, Seong KM, Youn H, Kim JW, Kim J, Youn B. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem. 2013; 288:27343-27357.
51. Kundu AK, Chandra PK, Hazari S, Pramar YV, Dash S, Mandal TK. Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm. 2012; 80:257-267.